Last reviewed · How we verify
Teriflunomide Oral Tablet
Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes.
Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes. Used for Relapsing-remitting multiple sclerosis (RRMS), Secondary progressive multiple sclerosis (SPMS).
At a glance
| Generic name | Teriflunomide Oral Tablet |
|---|---|
| Also known as | Gluten challenge |
| Sponsor | Oslo University Hospital |
| Drug class | Immunosuppressant; dihydroorotate dehydrogenase inhibitor |
| Target | Dihydroorotate dehydrogenase (DHODH) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Neurology |
| Phase | Phase 3 |
Mechanism of action
By blocking dihydroorotate dehydrogenase, teriflunomide depletes pyrimidine nucleotides needed for DNA and RNA synthesis, selectively suppressing the proliferation of activated T and B lymphocytes. This immunosuppressive effect reduces the inflammatory cascade underlying autoimmune diseases. The drug is the active metabolite of leflunomide and has a long half-life allowing once-daily oral dosing.
Approved indications
- Relapsing-remitting multiple sclerosis (RRMS)
- Secondary progressive multiple sclerosis (SPMS)
Common side effects
- Elevated liver enzymes (ALT/AST)
- Diarrhea
- Nausea
- Hair loss (alopecia)
- Headache
- Hypertension
- Peripheral neuropathy
Key clinical trials
- Leflunomide in Previously Treated Metastatic Triple Negative Cancers (PHASE1, PHASE2)
- Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (PHASE1, PHASE2)
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (PHASE3)
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (PHASE3)
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teriflunomide Oral Tablet CI brief — competitive landscape report
- Teriflunomide Oral Tablet updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI